How Caris Target Now Works

Caris Target Now provides the information oncologists need to individualize therapy regimens for their cancer patients. By utilizing the latest molecular profiling technologies to determine the unique biomarkers of a patient’s tumor, and performing an extensive review of clinical literature correlating biomarkers to drug response, Caris Target Now can help reveal the benefit (or lack of benefit) of specific therapeutic agents:

Immunohistochemistry (IHC)

– Determines level of protein expression

Fluorescence in situ hybridization (FISH)*

– Detects gene deletions, amplifications, translocations and fusions

DNA sequencing*

– Identifies mutations in a targeted gene by determining the DNA sequence

Microarray analysis*

– Measures the level of RNA expression for tens of thousands of genes

Quantitative polymerase chain reaction (qPCR)*

– Amplifies and simultaneously quantifies a targeted DNA molecule

Maintains an up-to-date data repository of the world’s most relevant clinical literature

Uses an accepted and standard grading system from the U.S. Preventive Services Task Force

Utilizes information from peer-reviewed clinical literature – more than 100,000 manuscripts reviewed

Evaluates studies based on the strength of clinical evidence that supports associations between biomarkers and treatments

Performs literature reviews using on-staff PhD scientists, oncologists and pathologists

* Certain tests may require a New York State non-permitted laboratory test request approval. Contact Caris Target Now Client Services for more information.

Biomarkers can provide valuable information on therapy effectiveness, but they’re often overlooked for many tumor types. Caris Target Now looks at biomarkers across tumor types both on- and off-NCCN compendium, potentially revealing treatments not previously considered:

Data on file. Data is not intended as a therapy recommendation. Caris Target Now provides specific biomarker information and associated literature references for related drug regimens. The information provided in a Caris Target Now report should be used in conjunction with other pertinent clinical information.

Caris Target Now was developed and its performance characteristics were determined by Caris Life Sciences, a medical laboratory CLIA-certified in compliance with the U.S. Clinical Laboratory Amendment Act of 1988 and all relevant U.S. state regulations. It has not been approved by the United States Food and Drug Administration.